With primary endpoint-missing phase IIb data in hand, Otonomy Inc. CEO David Weber told BioWorld Today that he is "more confident today" that OTO-104 for Meniere's disease is a viable product, and the company will be meeting with the FDA to talk about the planned phase III program.